Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Small intestinal neuroendocrine tumours
What changed

Small intestinal neuroendocrine tumours

What changed: Small intestinal neuroendocrine tumours

Cancer page →

Every dated change on the records linked to Small intestinal neuroendocrine tumours, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Overview Types and stages Symptoms and diagnosis Treatment Trials and papers Biology and targets Countries and centres Decisions and support Pipeline and open problems Data

Approval1Trial result6Milestone10This record1On Edge

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordSmall intestinal neuroendocrine tumours
Facts on this page last checked
When this page itself was last checked or edited.

2025 · 3

2025ApprovalPaltusotine
Paltusotine approved in US
Acromegaly in adults
2025Trial resultCOMPETE
COMPETE reported
PFS 23.
2025MilestoneCabozantinib
Cabozantinib approved for previously treated neuroendocrine tumours; COMPETE published
A milestone in how this cancer is treated.

2024 · 2

2024Trial resultCABINET (Alliance A021602)
CABINET (Alliance A021602) reported
PFS HR 0.
2024MilestoneStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
NETTER-2: lutetium-177 dotatate first line for grade 2 to 3 tumours; CABINET published
A milestone in how this cancer is treated.

2018 · 1

2018MilestoneLutetium-177 dotatate
Lutathera approved in the United States and Europe
A milestone in how this cancer is treated.

2017 · 2

2017Trial resultNETTER-1
NETTER-1 reported
PFS at 20 months 65.
2017MilestoneNETTER-1
NETTER-1 published; telotristat ethyl approved for carcinoid syndrome diarrhoea
A milestone in how this cancer is treated.

2016 · 1

2016MilestoneRADIANT-3 and RADIANT-4
RADIANT-4 extends everolimus to gut and lung tumours; gallium-68 DOTATATE PET approved
A milestone in how this cancer is treated.

2014 · 2

2014Trial resultCLARINET
CLARINET reported
PFS HR 0.
2014MilestoneCLARINET
CLARINET: lanreotide halves the risk of progression in enteropancreatic tumours
A milestone in how this cancer is treated.

2011 · 1

2011Trial resultRADIANT-3 and RADIANT-4
RADIANT-3 and RADIANT-4 reported
PFS HR 0.

2009 · 2

2009Trial resultPROMID
PROMID reported
TTP 14.
2009MilestonePROMID
PROMID: octreotide LAR slows midgut tumour growth
A milestone in how this cancer is treated.

1988 · 1

1988MilestoneSomatostatin analogues (octreotide, lanreotide)
Octreotide approved for carcinoid syndrome symptoms
A milestone in how this cancer is treated.

1954 · 1

1954MilestoneCarcinoid syndrome and carcinoid heart disease
Carcinoid syndrome described
A milestone in how this cancer is treated.

1907 · 1

1907MilestoneSmall intestinal neuroendocrine tumours
Oberndorfer names the small bowel tumours 'Karzinoid'
A milestone in how this cancer is treated.